New drug safety check for Hard-to-Treat prostate cancer
NCT ID NCT06733337
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 36 times
Summary
This study looks at the safety of the drug TALZENNA in men whose prostate cancer has spread and no longer responds to hormone therapy, and who have a BRCA gene mutation. Only one participant is being enrolled, and all will receive TALZENNA as prescribed. The main goal is to track side effects over up to 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Japan
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.